MRNA Stock Recent News

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for all individuals aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements.

mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).[1] "The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna, Inc. (NASDAQ:MRNA ) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Courtney Breen So I am thrilled to be here today with Stephane Bancel from Moderna. My name is Courtney Breen.

The Department of Health and Human Services announced this week that it had canceled its contract with Moderna to develop a bird flu mRNA vaccine for humans. In a statement, the department wrote that the deal was not "scientifically or ethically justifiable.

The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.

CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.

The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmaker.

Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.

Subscribers to  Chart of the Week  received this commentary on Sunday, May 11.

CAMBRIDGE, MA / ACCESS Newswire / May 27, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Jefferies Global Health Care Conference, on Thursday, June 5th at 10:30am ET Goldman Sachs 46th Annual Global Healthcare Conference, on Wednesday, June 11th at 8:40am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.